Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

30-10-2018 | Colorectal cancer | ESMO 2018 | Video

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC

Heinz-Josef Lenz outlines the results of CheckMate-142 study investigating combination immunotherapy in the first-line treatment of patients with MSI-high metastatic colorectal cancer, and discusses the unmet needs of those with MSI-low tumors (5:58).

Image Credits